Freedland, S. J., Giorgi, U. D., Tutrone, R. F., Karsh, L. I., Ramirez-Backhaus, M., Uchio, E. M., Tang, Y., Croitoru, R., Rosales, M., Kalac, M., Wang, F., Shore, N. D. (2025). Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5103